74 related articles for article (PubMed ID: 19369677)
1. Giant osteoclast formation and long-term oral bisphosphonate therapy.
Jobke B
N Engl J Med; 2009 Apr; 360(16):1676; author reply 1677-8. PubMed ID: 19369677
[No Abstract] [Full Text] [Related]
2. Giant osteoclast formation and long-term oral bisphosphonate therapy.
Roos JC; Cox TM
N Engl J Med; 2009 Apr; 360(16):1676-7; author reply 1677-8. PubMed ID: 19373965
[No Abstract] [Full Text] [Related]
3. The deceiving appearances of osteoclasts.
Glowacki J
N Engl J Med; 2009 Jan; 360(1):80-2. PubMed ID: 19118309
[No Abstract] [Full Text] [Related]
4. Giant osteoclast formation and long-term oral bisphosphonate therapy.
Weinstein RS; Roberson PK; Manolagas SC
N Engl J Med; 2009 Jan; 360(1):53-62. PubMed ID: 19118304
[TBL] [Abstract][Full Text] [Related]
5. Tetracyclines inhibit rat osteoclast formation and activity in vitro and affect bone turnover in young rats in vivo.
Zhou X; Zhang P; Zhang C; An B; Zhu Z
Calcif Tissue Int; 2010 Feb; 86(2):163-71. PubMed ID: 20033141
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
Ruggiero SL; Fantasia J; Carlson E
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
[No Abstract] [Full Text] [Related]
8. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
Armamento-Villareal R; Napoli N; Diemer K; Watkins M; Civitelli R; Teitelbaum S; Novack D
Calcif Tissue Int; 2009 Jul; 85(1):37-44. PubMed ID: 19548019
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
Drake MT; Cremers SC
Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
[TBL] [Abstract][Full Text] [Related]
11. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
13. Role of the osteoclast in cranial suture waveform patterning.
Byron CD
Anat Rec A Discov Mol Cell Evol Biol; 2006 May; 288(5):552-63. PubMed ID: 16604542
[TBL] [Abstract][Full Text] [Related]
14. Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
Tanaka T; Saito M; Chazono M; Kumagae Y; Kikuchi T; Kitasato S; Marumo K
J Biomed Mater Res A; 2010 May; 93(2):469-74. PubMed ID: 19582838
[TBL] [Abstract][Full Text] [Related]
15. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
Lee CY; Suzuki JB
Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
[TBL] [Abstract][Full Text] [Related]
16. Rationale for the potential use of calcitonin in osteoarthritis.
Manicourt DH; Devogelaer JP; Azria M; Silverman S
J Musculoskelet Neuronal Interact; 2005; 5(3):285-93. PubMed ID: 16172519
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of tiludronate in horses after long-term immobilization.
Delguste C; Amory H; Doucet M; Piccot-Crézollet C; Thibaud D; Garnero P; Detilleux J; Lepage OM
Bone; 2007 Sep; 41(3):414-21. PubMed ID: 17604709
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of Charcot neuroosteoarthropathy.
Jostel A; Jude EB
Clin Podiatr Med Surg; 2008 Jan; 25(1):63-9, vi-vii. PubMed ID: 18165112
[TBL] [Abstract][Full Text] [Related]
19. [Bisphosphonate therapy for osteoporosis and bone strength].
Kishimoto H
Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
[TBL] [Abstract][Full Text] [Related]
20. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
